Terms: = Breast cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Prognosis
73 results:
1. Metastatic Lymph Node 64 (MLN64) Expression in Gastric cancer: The Clinical and Molecular Implications in Drug Resistance.
Li AX; Zeng JJ; Khan E; Dou QP; Zhuang X; Ji EK; Ruge F; Martin TA; Jia S; Jiang WG
Cancer Genomics Proteomics; 2024; 21(1):30-40. PubMed ID: 38151289
[TBL] [Abstract] [Full Text] [Related]
2. Etoposide-induced MicroRNA-205-5p Suppresses Proliferation and Migration by Targeting erbb4 in MCF-7 Cells.
Son SW; Heo SH; Oh SS; Lee CH; Park JK
Anticancer Res; 2022 Sep; 42(9):4265-4272. PubMed ID: 36039421
[TBL] [Abstract] [Full Text] [Related]
3. Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease.
Soosanabadi M; Ghahfarokhi AM; Pourghazi F; Ehtesham N; Mirfakhraie R; Atanesyan L; Keyhani E; Behjati F
Mol Biol Rep; 2022 Sep; 49(9):8547-8553. PubMed ID: 35763181
[TBL] [Abstract] [Full Text] [Related]
4. The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer.
Yang C; Shangguan C; Lou G; Qu Q
Ann Palliat Med; 2022 Jan; 11(1):332-338. PubMed ID: 35144424
[TBL] [Abstract] [Full Text] [Related]
5. [Application of neratinib in the treatment of hormone receptor and HER-2 double positive breast cancer].
Wang X; Yuan P
Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):511-515. PubMed ID: 34034468
[TBL] [Abstract] [Full Text] [Related]
6. Neratinib in the early-stage/extended adjuvant breast cancer patient.
O'Shaughnessy JA; Isaacs C; O'Regan R
Clin Adv Hematol Oncol; 2020 Aug; 18 Suppl 12(8):1-20. PubMed ID: 33843843
[TBL] [Abstract] [Full Text] [Related]
7. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
8. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
Wang W; Zhao HF; Yao TF; Gong H
Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245
[TBL] [Abstract] [Full Text] [Related]
9. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract] [Full Text] [Related]
10. ErbB Receptors and cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract] [Full Text] [Related]
11. Human epidermal growth factor receptor 4 (her4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis.
Wang J; Yin J; Yang Q; Ding F; Chen X; Li B; Tian X
Oncotarget; 2016 Nov; 7(47):76693-76703. PubMed ID: 27736797
[TBL] [Abstract] [Full Text] [Related]
12. Immunohistochemical expression of human epidermal growth factor receptor (HER)-4 and prognosis in patients with metastatic breast cancer.
Deligonul A; Evrensel T; Avci N; Ugras N; Ture M; Cubukcu E; Hartavi M; Fatih Olmez O; Kurt E; Tolunay S; Kanat O; Manavoglu O
J BUON; 2016; 21(3):564-9. PubMed ID: 27569073
[TBL] [Abstract] [Full Text] [Related]
13. Metaplastic breast cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution.
Edenfield J; Schammel C; Collins J; Schammel D; Edenfield WJ
Clin Breast Cancer; 2017 Feb; 17(1):e1-e10. PubMed ID: 27568101
[TBL] [Abstract] [Full Text] [Related]
14. Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and breast cancer Cell Motility via Hypoxia-Inducible Factor 1α.
Lopez-Haber C; Barrio-Real L; Casado-Medrano V; Kazanietz MG
Mol Cell Biol; 2016 Aug; 36(15):2011-26. PubMed ID: 27185877
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of erbb4 expression in patients with triple negative breast cancer.
Kim JY; Jung HH; Do IG; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Park YH; Im YH
BMC Cancer; 2016 Feb; 16():138. PubMed ID: 26907936
[TBL] [Abstract] [Full Text] [Related]
16. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy.
Chen K; Yang D; Li X; Sun B; Song F; Cao W; Brat DJ; Gao Z; Li H; Liang H; Zhao Y; Zheng H; Li M; Buckner J; Patterson SD; Ye X; Reinhard C; Bhathena A; Joshi D; Mischel PS; Croce CM; Wang YM; Raghavakaimal S; Li H; Lu X; Pan Y; Chang H; Ba S; Luo L; Cavenee WK; Zhang W; Hao X
Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1107-12. PubMed ID: 25583476
[TBL] [Abstract] [Full Text] [Related]
17. Roles of the WWOX in pathogenesis and endocrine therapy of breast cancer.
Li J; Liu J; Ren Y; Liu P
Exp Biol Med (Maywood); 2015 Mar; 240(3):324-8. PubMed ID: 25476151
[TBL] [Abstract] [Full Text] [Related]
18. ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer.
Jerjees DA; Alabdullah M; Alkaabi M; Abduljabbar R; Muftah A; Nolan C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Aug; 147(1):25-37. PubMed ID: 25085753
[TBL] [Abstract] [Full Text] [Related]
19. Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer.
Hashimoto K; Tsuda H; Koizumi F; Shimizu C; Yonemori K; Ando M; Kodaira M; Yunokawa M; Fujiwara Y; Tamura K
Ann Oncol; 2014 Oct; 25(10):1973-1979. PubMed ID: 25009009
[TBL] [Abstract] [Full Text] [Related]
20. The localization of her4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.
Fujiwara S; Hung M; Yamamoto-Ibusuk CM; Yamamoto Y; Yamamoto S; Tomiguchi M; Takeshita T; Hayashi M; Sueta A; Iwase H
Oncotarget; 2014 Jun; 5(11):3919-30. PubMed ID: 25003574
[TBL] [Abstract] [Full Text] [Related]
[Next]
